Open-face masks improved head and neck RT experience without compromising setup accuracy
In the randomized OPEN trial, SGRT-supported open masks maintained setup accuracy while reducing distress and improving treatment experience.
In the randomized OPEN trial, SGRT-supported open masks maintained setup accuracy while reducing distress and improving treatment experience.
IPTW-weighted response was 71.1% versus 37.6%, with median survival 23.0 versus 15.6 months after adding SBRT.
Failure-free survival was 96.6% at 12 months, while grade 3 GU toxicity increased to 12.5% by one year.
Compressing three HDR brachytherapy fractions into one week shortened overall treatment time and increased early complete response without improving survival.
Personalized ctDNA was detected in 85% at baseline and remained independently prognostic before treatment, after radiotherapy and after surgery.
An integrated CT-linac workflow delivered emergency radiotherapy in 24.7 minutes, with symptom relief in nearly 90% of patients.
DEGRO supports postoperative radiotherapy within eight weeks while expanding hypofractionated options for frail and selected Merkel cell carcinoma patients.
Radical radiotherapy use nearly doubled while five-year lung cancer-specific survival rose from 21.9% to 33.1% across Northern Ireland.
After resection of ipsilateral recurrence, five-year locoregional recurrence-free survival was 84.2%, while grade 3 late toxicity was 3.9%.
With 42.56 Gy in 16 fractions, three-year lymphedema was 6.4%, with no new events through five years.
ESTRO consensus recommendations establish standardized dose, delivery, shielding and quality-assurance principles for total skin electron therapy.
Reduced ipsilateral mucosal irradiation produced 90% five-year survival in p16-positive unknown-primary disease, with no out-of-field mucosal or neck failures.
Median survival was 25 versus 18 months with chemotherapy plus definitive pelvic radiotherapy after propensity matching in stage IVB cervical cancer.
Four-year biochemical control was similar with 65 Gy in 26 fractions and 66 Gy in 33 fractions, while gastrointestinal toxicity was higher.
Twelve-month TME-free survival was 78.5% with long-course chemoradiotherapy versus 60.6% with short-course radiotherapy in early rectal cancer.